Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection. Gut 68 (10), pp. 1791-1800. 10.1136/gutjnl-2018-317842 file

Publishers page: http://dx.doi.org/10.1136/gutjnl-2018-317842
<http://dx.doi.org/10.1136/gutjnl-2018-317842>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher’s version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.
Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection

Benjamin H Mullish,†1 Julie A K McDonald,†1 Alexandros Pechlivanis,†1 Jessica R Allegretti,2,3 Dina Kao,4 Grace F Barker,†1 Diya Kapila,†1 Elaine O Petrof,5 Susan A Joyce,6,7 Cormac G M Gahan,6,8 Izabela Glegola-Madejska,9 Horace R T Williams,†1 Elaine Holmes,†1 Thomas B Clarke,9 Mark R Thurst,†1 Julian R Marchesi1,10

ABSTRACT

Objective Faecal microbiota transplant (FMT) effectively treats recurrent Clostridioides difficile infection (rCDI), but its mechanisms of action remain poorly defined. Certain bile acids affect C. difficile germination or vegetative growth. We hypothesised that loss of gut microbiota-derived bile salt hydrolases (BSHs) predisposes to CDI by perturbing gut bile metabolism, and that BSH restitution is a key mediator of FMT’s efficacy in treating the condition.

Design Using stool collected from patients and donors pre-FMT/post-FMT for rCDI, we performed 16S rRNA gene sequencing, ultra performance liquid chromatography mass spectrometry (UPLC-MS) bile acid profiling, BSH activity measurement, and qPCR of bsh/bai/CD genes involved in bile metabolism. Human data were validated in C. difficile batch cultures and a C57BL/6 mouse model of rCDI.

Results From metataxonomics, pre-FMT stool demonstrated a reduced proportion of BSH-producing bacterial species compared with donors/post-FMT. Pre-FMT stool was enriched in taurocholic acid (TCA, a potent C. difficile germinant); TCA levels negatively correlated with key bacterial genera containing BSH-producing organisms. Post-FMT samples demonstrated recovered BSH activity and bsh/bai/CD gene copy number compared with pretreatment (p<0.05). In batch cultures, supernatant from engineered bsh-expressing E. coli and naturally BSH-producing organisms (Bacteroides ovatus, Collinsella aerofaciens, Bacteroides vulgatus and Blautia obeum) reduced TCA-mediated C. difficile germination relative to culture supernatant of wild-type (BSH-negative) E. coli. C. difficile total viable counts were ~70% reduced in an rCDI mouse model after administration of E. coli expressing highly active BSH relative to mice administered BSH-negative E. coli (p<0.05).

Conclusion Restoration of gut BSH functionality contributes to the efficacy of FMT in treating rCDI.

INTRODUCTION

Clostridioides difficile (previously named Clostridium difficile) infection (CDI) is the major global cause of nosocomial GI infection, with incidence...
rates increasing worldwide.\(^2\)\(^3\) One therapeutic strategy for recurrent CDI (rCDI) that has come to prominence is faecal microbiota transplant (FMT). FMT has been demonstrated to be a highly effective therapy for rCDI, with cure rates of >80% in randomised trials,\(^4\) and up to >90% in case series where it was administered colonoscopically.\(^5\) However, FMT is not without drawbacks, including its unpalatability, the theoretical risk of administered colonoscopically.

Using the mechanisms underlying the efficacy of FMT in treating CDI may allow formulation of novel, more targeted, anti-CDI therapeutics. In a pilot study, sterile faecal filtrate was shown to be an effective treatment for rCDI in five patients,\(^6\) consistent with bacterially derived proteins, gut metabolites, bacteriophages or other filtrate components mediating the efficacy of FMT in treating this condition, as opposed to intact microorganisms. While the possible contribution of such mediators to FMT are starting to be elucidated,\(^8\)\(^9\)\(^10\) they remain incompletely defined.

One particular area of interest concerns the interaction between the gut microbiota and host bile acid metabolism in rCDI. In vitro, certain bile acids differentially affect the ability of \(C.\) difficile to undergo germination and vegetative growth. In particular, the conjugated primary bile acid taurocholic acid (TCA) is a potent trigger of \(C.\) difficile germination (with glycine as co-germinant),\(^11\) while the secondary bile acid deoxycholic acid (DCA) markedly inhibits vegetative growth.\(^11\)\(^12\) The transition from conjugated primary bile acids to secondary bile acids in vivo principally involves two enzymatic steps, with both enzymes produced by microbes but not mammals (see online supplementary figure 1). The first step is undertaken by bile salt hydrolases (BSHs), which deconjugate the taurine and glycine groups via a hydrolysis reaction, and consequently reform the unconjugated primary bile acids cholate and chenodeoxycholate. BSHs are widely distributed throughout most major bacterial divisions and archaea species of the gut microbiota, and at least eight different \(bsh\) genes exist\(^13\) (see online supplementary figure 2). The second enzymatic step is 7α-dehydroxylation, whereby unconjugated primary bile acids are converted to secondary bile acids, including deoxycholate and lithocholate.

At present, there are only limited data exploring the possible contribution of BSHs to CDI vulnerability,\(^14\) and none investigating the effect of FMT on BSH functionality. Given the key contribution of BSH’s substrate, TCA, to the germination of \(C.\) difficile, this is a clear potential mechanistic explanation for the efficacy of FMT. As such, using a work flow including human samples, batch cultures and mouse models, we investigated the efficacy of FMT. As such, using a work flow including human samples, batch cultures and mouse models, we investigated the efficacy of FMT. As such, using a work flow including human samples, batch cultures and mouse models, we investigated the efficacy of FMT. As such, using a work flow including human samples, batch cultures and mouse models, we investigated the efficacy of FMT.

Understanding the mechanisms underlying the efficacy of FMT in treating CDI may allow formulation of novel, more targeted, anti-CDI therapeutics. In a pilot study, sterile faecal filtrate was shown to be an effective treatment for rCDI in five patients,\(^6\) consistent with bacterially derived proteins, gut metabolites, bacteriophages or other filtrate components mediating the efficacy of FMT in treating this condition, as opposed to intact microorganisms. While the possible contribution of such mediators to FMT are starting to be elucidated,\(^8\)\(^9\)\(^10\) they remain incompletely defined.

One particular area of interest concerns the interaction between the gut microbiota and host bile acid metabolism in rCDI. In vitro, certain bile acids differentially affect the ability of \(C.\) difficile to undergo germination and vegetative growth. In particular, the conjugated primary bile acid taurocholic acid (TCA) is a potent trigger of \(C.\) difficile germination (with glycine as co-germinant),\(^11\) while the secondary bile acid deoxycholic acid (DCA) markedly inhibits vegetative growth.\(^11\)\(^12\) The transition from conjugated primary bile acids to secondary bile acids in vivo principally involves two enzymatic steps, with both enzymes produced by microbes but not mammals (see online supplementary figure 1). The first step is undertaken by bile salt hydrolases (BSHs), which deconjugate the taurine and glycine groups via a hydrolysis reaction, and consequently reform the unconjugated primary bile acids cholate and chenodeoxycholate. BSHs are widely distributed throughout most major bacterial divisions and archaea species of the gut microbiota, and at least eight different \(bsh\) genes exist\(^13\) (see online supplementary figure 2). The second enzymatic step is 7α-dehydroxylation, whereby unconjugated primary bile acids are converted to secondary bile acids, including deoxycholate and lithocholate.

At present, there are only limited data exploring the possible contribution of BSHs to CDI vulnerability,\(^14\) and none investigating the effect of FMT on BSH functionality. Given the key contribution of BSH’s substrate, TCA, to the germination of \(C.\) difficile, this is a clear potential mechanistic explanation for the efficacy of FMT. As such, using a work flow including human samples, batch cultures and mouse models, we investigated the hypothesis that patients with rCDI are deficient in gut microbiota members which produce BSH, with the consequent enrichment in TCA (promoting \(C.\) difficile germination) and loss of DCA (permitting vegetative growth) contributing to ongoing disease. We further hypothesised that successful FMT recolonises the gut microbiota with BSH-producing organisms, contributes to the restoration of the normal bile acid milieu of the gut, and consequently removes key triggers for \(C.\) difficile germination and vegetative growth.

**MATERIALS AND METHODS**

**Study participants and FMT protocols**

For the main human data set, stool samples were collected from participants with rCDI (26 participants; samples collected pre-FMT and at 8–12 weeks post-FMT) and their FMT donors (17 participants). rCDI was diagnosed on a combination of clinical and laboratory criteria (see online supplementary methods 1.1). Patient characteristics are described in online supplementary table 1; none of the included patients had IBD. For validation of initial findings, stool samples were also analysed for patients with rCDI from a Canadian randomised controlled trial investigating capsule versus colonoscopic FMT as rCDI treatment (18 participants; samples collected pre-FMT and at 1, 4 and 12 weeks post-FMT), together with donors (five participants).\(^15\) FMT slurry was also collected from these donors.

Donor inclusion/exclusion criteria, screening and testing followed previously described recommendations.\(^16\) FMT protocols used are detailed in online supplementary methods 1.1.

**DNA extraction and 16S rRNA gene sequencing**

DNA was extracted from 250 mg of stool using a previously described protocol.\(^17\) 16S rRNA gene qPCR data were used to determine total bacterial biomass within each sample (see online supplementary methods 1.2). Sample libraries were prepared following Illumina’s 16S Metagenomic Sequencing Library Preparation Protocol\(^18\) with several modifications.\(^19\) The V1-V2 regions of the 16S rRNA gene were amplified using previously reported primers.\(^17\) The methodology for metatranscriptomic analysis is described in online supplementary methods 1.3. We also predicted the bile metabolising ability of microbial communities using a metagenomic inferential tool, Pipihill\(^19\) (see online supplementary methods 1.4).

**UPLC-MS profiling of faecal bile acids**

The protocol used for initial sample processing\(^17\) and for analysis\(^20\) was as previously described. Methodology for preprocessing and analysis of ultra performance liquid chromatography mass spectrometry (UPLC-MS) bile acid data is described in online supplementary methods 1.5. Integration of metatranscriptomic and UPLC-MS bile profiling data is described in online supplementary methods 1.6.

**Abundance and activity of bile metabolising enzymes**

qPCR was performed using extracted DNA to quantify gene abundance for (1) specified groups of \(bsh\) (using degenerate primer sets previously reported)\(^17\) and (2) \(bat\) (using previously described primers)\(^21\) (see online supplementary methods 1.7). The BS activity assay was an adaptation of the conventional precipitation-based assay,\(^22\)\(^23\)\(^24\) using a previously described technique.\(^15\)

**C. difficile germination batch cultures**

These were performed via adaptation of a previously described protocol.\(^11\) \(C.\) difficile spore preparation and enumeration is described in online supplementary methods 1.8. A range of different bacterial species established to produce BSH from different BSH groups (and \(Clostridium\) scindens, as a known \(7\)-α-dehydroxylase-producer) were incubated in sBHI (brain heart infusion broth (Sigma-Aldrich), with 5 mg/mL yeast extract (Sigma-Aldrich), and 0.1% w/v L-cysteine (Sigma-Aldrich)), with or without 1% w/v TCA added (see online supplementary methods 1.7). This list also included wild-type \(E.\) coli MG1655 (which does not contain \(bsh\) genes within its genome), along with two forms of \(E.\) coli MG1655 into which \(bsh\) genes had been cloned using pBKminiTn7GM2 under the control of the P44 promoter\(^25\) (see online supplementary methods 1.7). \(C.\) difficile spores from three different ribotypes (a non-toxigenic ribotype, 010 (strain DS1684), and two toxigenic ribotypes, 012 and 013 MG1655 MG22085).
Gut microbiota

012 (strain CD630) and 027 (strain R20291) were resuspended in supernatant in triplicate, and an OD<sub>600</sub> reading taken on a microplate reader at time zero (adjusted to OD<sub>600</sub> of ~0.1 with supernatant/sBHI mix), and again after overnight incubation. An increased OD<sub>600</sub> reading after overnight incubation was interpreted as indicating that spores had undergone germination and had grown as vegetative cells. Additionally, UPLC-MS was performed on batch culture supernatants to establish bile acid profiles (see online supplementary methods 1.5.2), and BSH activity assays were performed on spent supernatant from selected batch cultures.

Recurrent C. difficile mouse model

Wild-type C57BL/6 mice (8–10 weeks old; female) were purchased from Envigo (Huntingdon, UK) and acclimatised for 1 week before use. Mice were housed five per cage in individually ventilated cages with autoclaved food (RM1, Special Diet Services, Essex, UK), bedding (Aspen chip two bedding, Northeastern Products Corporation (NEPCO), Warrensburg, New York) and water (provided ad libitum). Mice were subjected to a 12 hours light and 12 hours dark cycle at 20°C–22°C.

We adapted a previously published mouse model of rCDI/FMT (figure 1A). Mice were initially given cefoperazone 0.5 mg/mL (Melford, Ipswich, UK) in their drinking water for 5 days (day −7 to day −2), followed by challenge with 10<sup>5</sup> C. difficile spores by oral gavage on day 0. Mice were then treated with vancomycin 0.4 mg/mL together with streptomycin 5 mg/mL (both Melford, Ipswich, UK) in their drinking water for 3 days (days 4–7), followed by autoclaved antibiotic-free water for the remainder of the experiment. On both days 9 and 10, mice were fed by oral gavage either with −10<sup>5</sup> colony-forming units (CFUs) of wild-type E. coli (n = 5) or E. coli BSH<sub>high</sub> (n = 5) (see online supplementary methods 1.7). Serial faecal samples were collected and C. difficile total viable counts (TVCs) quantified until E. coli colonisation began to decline (see online supplementary methods 1.9). Administered E. coli were quantified by plating on MacConkey agar plates supplemented with rifampicin 50 µg/mL (Melford, Ipswich, UK). Mice were not fasted before oral gavages and all interventions were performed during the light cycle.

Statistical analysis

This is summarised in online supplementary methods 1.10.

RESULTS

Successful FMT for rCDI is associated with restoration of BSH-producing gut microbial community members from all BSH groups

We used microbial sequencing to evaluate whether FMT for rCDI was associated within an increase in BSH-producing microbes within the faecal microbiota. Further analysis of metataxonomic
Gut microbiota data is provided in online supplementary results, figures 3–5 and table 2.

Bacterial species enriched in the faecal microbiota of healthy donors compared with pre-FMT samples were characterised by a range of BSH-producing organisms, including members of group 1 (Bacteroides ovatus, q = 0.017; Bacteroides uniformis, q = 0.007), group 2 (Bifidobacterium dentium, q = 0.014; Collinsella aerofaciens, q = 0.009; Bifidobacterium longum, q = 0.011) and group 3 (Bacteroides vulgatus, q = 0.003; Faecalibacterium prausnitzii, q = 0.003; Eubacterium rectale, q = 0.005; Blautia obeum, q = 0.014) (figure 2A). Similarly, bacterial species enriched in the post-FMT faecal microbiota compared with those pre-FMT also included members of all BSH groups, including group 1 (Bacteroides uniformis, q = 0.005; Bacteroides ovatus, q = 0.009; Parabacteroides distasonis, q = 0.003), group 2 (Collinsella aerofaciens, q = 0.006; Bifidobacterium dentium, q = 0.029) and group 3 (Bacteroides vulgatus, q = 0.002; Eubacterium rectale, q = 0.004; Blautia obeum, q = 0.009; Faecalibacterium prausnitzii, q = 0.003) (figure 2B).

Using Piphillin to infer metagenomic content from metataxonomic data, there were a significantly reduced proportion of sequences predicted to represent both BSH (see online supplementary figure 6A) and 7-α-dehydroxylase (see online supplementary figure 6B) in pre-FMT samples compared with donors, but a significant increase in both post-FMT samples compared with pre-FMT (q < 0.01, White’s non-parametric test with Benjamini-Hochberg false discovery rate (FDR)).

Successful FMT for rCDI is associated with restoration of normal gut bile acid profiling, including a sustained reduction in TCA

On multivariate analysis of UPLC-MS bile acid profiling data, unsupervised principal component analysis demonstrated clustering of donor and post-FMT samples, but clear separation of both groups from pre-FMT samples (figure 3A). Supervised analysis was performed with orthogonal projections to latent structures discriminant analysis (OPLS-DA) to analyse the features responsible for discrimination between donor and pre-FMT groups (see online supplementary figure 7A), and between pre-FMT and post-FMT groups (figure 3B). Discriminatory feature identification was performed from OPLS-DA model data via S-plot, with pre-FMT samples showing an enrichment in primary bile acids (including both conjugated and unconjugated forms) and loss of secondary bile acids as compared with post-FMT and healthy donor samples (figure 3C, see online supplementary figure 7B). OPLS-DA model validation was performed using CV analysis of variance (see online supplementary table 3).

Univariate analysis supported these findings (see online supplementary figure 8). Pre-FMT samples demonstrated enrichment in TCA and loss of DCA compared with healthy donor samples (p < 0.01, Mann-Whitney U test), while post-FMT samples were characterised by restoration of both bile acids back to levels comparable to donors (p < 0.001, Wilcoxon signed rank-sum test).

Integration of metataxonomic and bile acid profiling data

rCCA modelling was used to integrate metataxonomic and bile acid profiling data. The unit representation plot demonstrated marked separation of pre-FMT and post-FMT samples, but considerable overlap between donor and post-FMT samples (figure 4A). A correlation circle plot demonstrated negative correlations between levels of TCA and the abundance of C. difficile to undergo germination or vegetative growth.
the bacterial genera *Bacteroides* and *Blautia*, both known to include representative BSH-producing organisms that were significantly increased after FMT in our metaxonomic data (figure 4B). In addition, there was positive correlation between the genus *Clostridium* cluster XIVa (known to contain 7-α-dehydroxylase producing organisms) and the secondary bile acids DCA and lithocholic acid (figure 4B).

**Gut bsh gene copy number and BSH enzyme activity is restored by successful FMT for rCDI**

Having established an association between restoration of BSH-producing organisms into the gut microbiota post-FMT and recovery of premorbid stool bile acid profiles, we investigated the effect of FMT for rCDI on BSH expression and activity.

---

**Figure 3** Effect of FMT for rCDI on stool bile acid profiles. Assessed via multivariate analysis of UPLC-MS bile acid profiling data. (A) PCA scores plot; (B) OPLS-DA scores plot, comparing pre-FMT and post-FMT samples; (C) OPLS-DA S-plot of pre-FMT versus post-FMT data. FMT, faecal microbiota transplant; OPLS-DA, orthogonal projections to latent structures discriminant analysis; PCA, principal component analysis; QC, quality controls; rCDI, recurrent *C. difficile* infection; UPLS-MS, ultra performance liquid chromatography mass spectrometry.

**Figure 4** Regularised CCA (rCCA) model correlating 16S rRNA gene sequencing data (genus level) and bile acid data. (A) Unit representation plot for the two canonical variables (metataxonomics and stool bile acids); (B) Correlation circle plot between pre-FMT and post-FMT samples. Bile acids are shown in blue and bacterial genera are shown in orange. FMT, faecal microbiota transplant.
Gut microbiota

bsh gene copy number was significantly reduced in pre-FMT samples compared with healthy donors across a range of bsh gene groups (p<0.001, Mann-Whitney U test, figure 5A–C). Successful FMT was associated with significant enrichment in copy number of all bsh gene groups assayed (p<0.05, Wilcoxon signed rank-sum test, for pre-FMT vs post-FMT). Similarly, copy numbers of the baiCD operon (encoding an enzyme that contributes to 7-α-dehydroxylation) were significantly lower in pre-FMT samples compared with those of healthy donors (p<0.01), but were also significantly enriched post-FMT (p<0.05, figure 5D). Gene copy number for baiCD in donors and post-FMT was noted to be markedly lower than for each bsh gene assayed for the same participants. Stool BSH enzyme activity showed the same pattern as for bsh gene copy number (figure 5E).

To further explore the timescale of gut bile acid/BSH changes post-FMT, we analysed serial stool samples collected from patients in a randomised trial of colonoscopy versus capsule FMT as treatment for rCDI, together with donor samples and FMT slurry itself. This demonstrated that BSH activity was restored (and stool TCA levels greatly reduced) to levels comparable to donors within a week of successful FMT, and was

Figure 5  Effect of FMT on bile-metabolising enzyme gene copy number and BSH enzyme activity. (A) bsh group 1A; (B) bsh group 1B; (C) bsh group 3C; (D) baiCD operon of 7-α-dehydroxylase; (E) BSH enzyme activity within faecal supernatant (*, p<0.05; **, p<0.01; ***; p<0.001; ****, p<0.0001; Mann-Whitney U test for donors versus pre-FMT, Wilcoxon signed rank-sum test for pre-FMT vs post-FMT). BSH, bile salt hydrolases; FMT, faecal microbiota transplant.
maintained at these levels at 4 weeks and 12 weeks post-FMT (p<0.05, Friedman test with Benjamini-Hochberg FDR; figure 6A,B). Similarly, BSH activity was significantly reduced in pre-FMT samples compared with either donor stool or FMT slurry (p<0.01, Mann-Whitney U test; figure 6B).

**BSH activity alone is sufficient to fully suppress TCA-mediated C. difficile germination in vitro**

Our data demonstrated an association between successful FMT, breakdown of TCA, and restoration of gut BSH-producing microorganisms and BSH functionality. To further explore whether these changes were purely associative—or represented a true mechanistic pathway—we performed C. difficile batch culture germination experiments.

We prepared spent culture supernatants by incubating bacteria of interest in broth with 1% w/v TCA. After overnight incubation, cultures were centrifuged and filter-sterilised. C. difficile spores were incubated in sBHI broth supplemented with the spent culture supernatant. Using this set-up, C. difficile spores incubated with spent culture supernatants without BSH activity would have TCA available to stimulate germination and therefore grow, while C. difficile spores incubated with spent culture supernatants with BSH activity would not have TCA available to stimulate germination and would not grow.

Initially, C. difficile spores were incubated with spent supernatant from BSH-expressing microorganisms that had been incubated with TCA. The microorganisms selected were those which had been shown to be reduced in mean proportion in the gut microbiota of pre-FMT patients in comparison to donors and/or post-FMT samples, and which collectively represented most BSH groups. For all C. difficile ribotypes assayed, supernatant from the broth of each of the BSH-producing microbes assayed significantly reduced C. difficile germination (p<0.0001) (figure 7A). As a control, we used spent supernatant from TCA-supplemented broth in which vegetative C. difficile had been cultured (strain DS1864); this failed to affect C. difficile germination.

We assessed whether BSH alone could mediate this inhibition, or if it reflected an alternative aspect of bacterial metabolism within the cultures. For subsequent batch cultures, strains of interest included wild-type E. coli (which lacks a bsh gene), or two forms of E. coli into which bsh genes had been cloned (ie, ‘E. coli BSH<low>’, containing a bsh gene with narrow substrate range against conjugated bile acids; and ‘E. coli BSH<high>’, containing a bsh gene with high glycine and taurine-deconjugating activity) (see online supplementary methods 1.7). While spent supernatant from the culture of wild-type/BSH-negative E. coli did not affect the ability of C. difficile to undergo germination, that from both forms of bsh gene-expressing E. coli significantly reduced C. difficile germination across all ribotypes tested (p<0.0001, Student’s t-test) (figure 7B). C. difficile germination was significantly lower for all three ribotypes when incubated in TCA-supplemented supernatant from an E. coli BSH<high> batch culture as compared with E. coli BSH<low> (p<0.05).

C. difficile spores were also cultured in spent supernatant from C. scindens which had been incubated with TCA, either by itself or also in co-culture with BSH-expressing E. coli. C. scindens spent supernatant did not affect C. difficile germination ability by itself, but germination was significantly reduced when C. scindens was co-incubated with BSH-expressing E. coli (p<0.01) (figure 7C).

Analysis by UPLC-MS confirmed that TCA-supplemented batch culture media—which included supernatant from wild-type/BSH-negative E. coli, vegetative C. difficile and C. scindens culture—had high TCA:CA ratios, consistent with little/absent BSH activity within these batch cultures.
Gut microbiota

Figure 7  C. difficile batch cultures. Changes in spectrophotometer reading (ΔOD_600) after overnight incubation of C. difficile spores (three ribotypes assayed: 010, 012, 027) in sBHI ±TCA in which bacterial species of interest had been cultured for 24 hours. C. difficile spores in sBHI supplemented with 1% TCA (’No supernatant, 1% TCA’) was used as positive control in all cases; statistical testing shown was performed relative to this sample for the particular ribotype under assessment. (A) Batch cultures of BSH-producing microbial species found to be affected by FMT in metataxonomic analysis, and vegetative C. difficile. (B) Batch cultures of native E. coli, and two forms of E. coli into which bsh genes had been cloned (E. coli BSH敲除=E. coli expressing BSH with low deconjugation ability; E. coli BSH敲除=E. coli expressing BSH with high deconjugation activity). (C) Batch cultures of C. scindens±BSH expressing E. coli (**, p<0.01; ****, p<0.0001; analysis of variance with multiple group comparisons, Benjamini-Hochberg correction). Key: 010 is a non-toxigenic C. difficile ribotype, while 012 and 027 are both toxigenic ribotypes. BHI, brain heart infusion; BSH, bile salt hydrolases; TCA, taurocholic acid.

BSH limits further recurrence of CDI in a mouse model of rCDI

To investigate the hypothesis that BSH-producing bacteria limit further recurrence of disease in subjects with rCDI, we administered $-10^9$ CFU of either wild-type/BSH-negative E. coli or E. coli BSH敲除 (n=5 in both groups) into a mouse model of rCDI shortly after completion of vancomycin (figure 1A). We used this particular protocol to aim to recapitulate the dynamics of FMT administration to patients with rCDI. Colonisation of all mice with C. difficile was demonstrated at 3 days post-C. difficile spore administration (see online supplementary figure 10A), and plate counts were used to confirm the titre of E. coli administered to mice (see online supplementary figure 10B). E. coli colonisation of the gut of mice was assessed by plate counts on selective media; we identified that on day 12 (ie, 3 days after initial E. coli administration), E. coli colonisation was at comparable, high levels in both groups of mice (mean CFU per gram of faeces of $1.49\times10^9$ in mice administered E. coli BSH敲除 vs. $1.18\times10^9$ in mice administered wild-type E. coli, p>0.05, Mann-Whitney U test) (figure 1B).

On day 12, C. difficile TVCs were significantly reduced in the mice administered E. coli BSH敲除 in comparison to those administered wild-type/BSH-negative E. coli (figure 1C; mean CFU per gram of faeces of $6.92\times10^7$ vs. $2.70\times10^8$, respectively; p<0.05, Mann-Whitney U test), equating to a $\sim$70% reduction in C. difficile total vegetative cell counts.

DISCUSSION

In this study, we demonstrate for the first time that a key mechanism underlying the efficacy of FMT in treating rCDI is restoration of gut microbiota BSH functionality. Analysis of human samples illustrate that this function is restored early after FMT and maintained throughout follow-up. In addition, data from batch cultures and mouse modelling show that the BSH-mediated hydrolysis of the major C. difficile germinant, TCA, is sufficient to fully suppress C. difficile germination, and limits further recurrence of disease within the setting of rCDI. Targeted restoration of gut BSH function is a novel therapeutic approach for rCDI that avoids the risks associated with FMT.

The potential role of gut microbiota-host bile acid interactions in CDI pathogenesis has been an area of interest since initial studies in vitro established that various bile acids differentially affected the ability of C. difficile to undergo germination and vegetative growth. Furthermore, we have also recently demonstrated that successful FMT for rCDI is associated with stimulation of farnesoid X receptor (FXR) signalling, which in itself appears to impact the bile acid milieu and consequently gut microbiota of the small intestine. Subsequent studies have demonstrated that the gut of germ-free and antibiotic-treated mice –as well as chemostat models of CDI or humans with rCDI –have enrichment of stool primary bile acids (particularly conjugated versions) and loss of secondary bile acids, with bile acid homeostasis being restored in patients with rCDI through FMT. Exposure of C. difficile spores to the bile acid milieu found in antibiotic-treated mouse caecum or human stool pre-FMT was sufficient to cause spore germination, while that of the non-antibiotic-treated mouse caecum or human stool post-FMT prevented germination and vegetative growth of C. difficile.

Rodent studies have demonstrated that 7-α-dehydroxylase-producing organisms (in particular, C. scindens) partly protected the host against the development of CDI. However, to date, there is not sufficient evidence to demonstrate that 7-α-dehydroxylase is responsible for the efficacy of FMT for rCDI. For example,
In conclusion, we provide evidence for the first time that microbial BSHs are a key mediator of the efficacy of FMT for rCDI. This adds to other recent data demonstrating that FMT functions by reversing a ‘metabolic dysbiosis’, including through the restoration of the short chain fatty acid valerate, which potently inhibits the growth of \textit{C. difficile} without any apparent adverse effect on gut commensal bacteria. Furthermore, these data add further to the growing body of evidence demonstrating the central significance of gut microbiota-bile acid interactions in colonisation resistance, and demonstrate that targeted restitution of BSH may be a novel therapy for or preventative strategy against CDI that avoids the risks of antimicrobial resistance.

Author affiliations
1 Division of Integrative Systems Medicine and Digestive Disease, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK
2 Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women’s Hospital, Boston, Massachusetts, USA
3 Harvard Medical School, Harvard University, Boston, Massachusetts, USA
4 Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
5 Division of Infectious Diseases/GI Diseases Research Unit Wing, Department of Medicine, Kingston General Hospital, Queen’s University, Kingston, Ontario, Canada
6 APC Microbiome Institute, University College Cork, Cork, Ireland
7 School of Biochemistry and Cell Biology, University College Cork, Cork, Ireland
8 School of Pharmacy, University College Cork, Cork, Ireland
9 MRC Centre for Molecular Bacteriology and Infection, Imperial College London, London, UK
10 School of Biosciences, Cardiff University, Cardiff, UK

Acknowledgements
bsh gene-expressing \textit{E. coli} were provided by SAJ and CGMG. APC Microbiome Institute, University College Cork, Cork, Ireland. The authors wish to thank Douglas N Rees for laboratory technical support, Dr Stephen P Atkinson for support with data analysis, Mr Chris Mack for support with the mouse work and Mr Matt Embreg for help with administration related to sample preparation and shipment.

Contributors
BHM and JAKM were involved in all aspects of experimental work and data analysis; JRA, DK and EOP provided samples and contributed to data analysis; AP and EH provided analysis of mass spectrometry data; GFB and DK performed qPCR and data analysis; SAJ and CGMG provided bacteria and aided analysis of batch culture experiments; BHM, JAKM, IG-M and TBC performed the mouse experiments; HRTW, MRT and JRM contributed to study design and provided overall supervision of experimental work and data analysis. All authors contributed to and approved the final manuscript.

Funding
The Division of Integrative Systems Medicine and Digestive Disease at Imperial College London receives financial support from the National Institute of Health Research (NIHR) Imperial Biomedical Research Centre (BRC) based at Imperial College Healthcare NHS Trust and Imperial College London. This paper is independently funded by the NIHR BRC, and the views expressed in this publication are those of the authors, and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. BHM is the recipient of a Medical Research Council (MRC) Clinical Research Training Fellowship (grant reference: MR/R000875/1). DK receives research funding from Alberta Health Services and University of Alberta Hospital Foundation. EOP is supported by the Southern Ontario Academic Medical Organization, and National Institutes of Health Grant (R33/ AI21575). SAJ and CG are funded by SFI 12/RC/2273 to APC Microbiome Institute and SFI 16/ERA-HDHL/3358 (to SAJ). TBC is a Sir Henry Dale Fellow jointly funded by the Wellcome Trust and Royal Society (grant 107662/Z/15/Z).

Competing interests
JRA consults for Finch Therapeutics. DK has received research funding from Rebiotix. EOP is a co-founder of NubiJetta and serves on its scientific advisory board. All other authors declared no conflict of interests.

Patient consent for publication
Not required.

Ethics approval
This study received approval from the UK National Research Ethics Centres (13/LO/1867) and REB approval from all participating institutions. Mouse experiments were performed under the authority of the UK Home Office outlined in the Animals (Scientific Procedures) Act 1986 after ethical review by the Imperial College London Animal Welfare and Ethical Review Body (PPL 70/7969). Standards articulated in the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines were adhered to.

Provenance and peer review
Not commissioned; externally peer reviewed.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits...
other to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

REFERENCES

1. Lawson PA, Citron DM, Tyrell KL, et al. Reclassification of Clostridium difficile as Clostridium difficile (Hall and Toole 1935) Préval 1938. Anaerobe 2016;40:59–63.
2. Ma GK, Bersinger CM, Wu Q, et al. Increasing Incidence of Mutiple Recurrent Clostridium difficile infection in the United States: A Cohort Study. Ann Intern Med 2017;167:152–8.
3. King A, Mullish BH, Williams HRT, et al. Comparative epidemiology of Clostridium difficile infection: England and the USA. Int J Qual Health Care 2017;29:785–91.
4. Mullish BH, Quraishi MN, Segal JP, et al. Bile salts and glycine as cogerminants for Clostridium difficile bacteria. Gut 2013;62:1142–53.
5. Mullish BH, Williams HRT, et al. Challenges to establishing a national faecal transplant programme. BMJ 2015;351:h6043.
6. Ott SJ, Waetzig GH, Rehman A, et al. Efficacy of sterile faecal filtrate for treating patients with Clostridium difficile infection. Gastroenterology 2017;152:799–811.
7. McDonald JA, Mullish BH, Chelvanayagam G, et al. Inhibiting growth of Clostridium difficile by restoring valerate, produced by the intestinal microbiota. Anaerobe 2018;55:1495–507.
8. Zuo T, Wong SH, Lam K, et al. Bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile infection is associated with treatment outcome. Gut 2018;67:634–43.
9. Mullish BH, Williams HR. Obstacles to establishing an NHS faecal transplant programme. BMJ 2015;351:h6043.
10. Ott SJ, Waetzig GH, Rehman A, et al. Efficacy of sterile faecal filtrate for treating patients with Clostridium difficile infection. Gastroenterology 2017;152:799–811.
11. King A, Mullish BH, Williams HRT, et al. Comparative epidemiology of Clostridium difficile infection: England and the USA. Int J Qual Health Care 2017;29:785–91.
12. McDonald JA, Mullish BH, Chelvanayagam G, et al. Inhibiting growth of Clostridium difficile by restoring valerate, produced by the intestinal microbiota. Anaerobe 2018;55:1495–507.
13. Zuo T, Wong SH, Lam K, et al. Bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile infection is associated with treatment outcome. Gut 2018;67:634–43.
14. Mullish BH, Williams HR. Obstacles to establishing an NHS faecal transplant programme. BMJ 2015;351:h6043.
15. Ott SJ, Waetzig GH, Rehman A, et al. Efficacy of sterile faecal filtrate for treating patients with Clostridium difficile infection. Gastroenterology 2017;152:799–811.
16. McDonald JA, Mullish BH, Chelvanayagam G, et al. Inhibiting growth of Clostridium difficile by restoring valerate, produced by the intestinal microbiota. Anaerobe 2018;55:1495–507.
17. Zuo T, Wong SH, Lam K, et al. Bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile infection is associated with treatment outcome. Gut 2018;67:634–43.
18. Mullish BH, Williams HR. Obstacles to establishing an NHS faecal transplant programme. BMJ 2015;351:h6043.